{"metadata": {"source": "pubchem", "title": "Methadone | C21H27NO | CID 4095 - PubChem", "description": "Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/4095", "drug": "Methadone", "cid": 4095, "char_count": 207830, "word_count": 28065, "doc_id": "doc_48", "num_chunks": 289, "chunk_id": "48::chunk_6", "document_index": 48, "latency_s": 1.735201399991638, "prompt_toks": 53767, "completion_toks": 75, "relevance_score": 1.0289513e-05}, "content": "Drug: Methadone | cid: 4095\nSource: pubchem | Source description: Methadone | C21H27NO | CID 4095 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    substances that increase the risk of harm or overdose. Provision of OAT is often combined with education about harm reduction including use of clean needles and injection supplies in an effort to reduce the risks associated with injection drug use such as contraction of HIV and Hepatitis C and other complications including skin infections, abscesses, or endocarditis.\n\n\n                    Context: \n                    This excerpt appears within the section on drug and medication safety, specifically discussing harm reduction strategies associated with opioid substitution therapy (OAT) such as methadone. It highlights that provision of OAT should be accompanied by education on safe injection practices to mitigate risks like infections and overdose, emphasizing the importance of harm reduction in the overall context of opioid treatment safety and public health information.\n                "}
{"metadata": {"source": "pubchem", "title": "Buprenorphine | C29H41NO4 | CID 644073 - PubChem", "description": "Buprenorphine | C29H41NO4 | CID 644073 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.", "language": "en", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/644073", "drug": "Buprenorphine", "cid": 644073, "char_count": 98200, "word_count": 12186, "doc_id": "doc_25", "num_chunks": 128, "chunk_id": "25::chunk_64", "document_index": 25, "latency_s": 1.3336401999986265, "prompt_toks": 25432, "completion_toks": 96, "relevance_score": 5.9087965e-06}, "content": "Drug: Buprenorphine | cid: 644073\nSource: pubchem | Source description: Buprenorphine | C29H41NO4 | CID 644073 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.\n\n                    Text: \n                    Pearls of Wisdom\n\nBuprenorphine acts as a partial agonist at the mu-opioid receptor and is generally considered safer than methadone. However, combining it with other CNS depressants, such as alcohol or benzodiazepines, can lead to respiratory depression and should be avoided.\n\nIf an overdose occurs with buprenorphine, significantly higher doses of naloxone, along with other supportive measures, are necessary.\n\nDue to its partial opioid agonist nature, the drug has a lower potential for dependence and misuse compared to pure agonists such as heroin or morphine; however, it can still be misused.\n\nIncorporating naloxone into the formula is intended to further reduce the risk of substance misuse by injection but does not always eliminate the risk.\n\nUnlike methadone, the therapeutic dose of buprenorphine can be titrated to a stable dose within several days. In contrast, methadone often takes many weeks or even months to reach a therapeutic dose.\n\n\n                    Context: \n                    This excerpt provides key clinical insights and safety tips about buprenorphine, highlighting its mechanism as a partial mu-opioid receptor agonist, safety profile compared to methadone, and overdose management with naloxone. It emphasizes precautions when combining with CNS depressants and the advantages of dose titration, making it relevant for understanding buprenorphine’s pharmacology, safety, and clinical use within the comprehensive chemical and pharmacological profile presented in the full document.\n                "}
{"metadata": {"source": "psychonaut", "title": "Methadone - PsychonautWiki", "description": "Methadone (sold under trade names such as Dolophine and Methadose) is a synthetic opioid analgesic used for the treatment of moderate to severe pain and for the treatment of opioid addiction. It is commonly used to treat and manage the symptoms of opioid addiction. The subjective effects are similar to those of other synthetic opioids such as fentanyl, however, most users note a significantly stronger euphoria. Like dextropropoxyphene, the use of methadone is associated with cardiac arrhythmia, however it is more common with dextropropoxyphene than it is with methadone.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/Methadone", "drug": "Methadone", "cid": 4095, "char_count": 21869, "word_count": 3171, "doc_id": "doc_87", "num_chunks": 31, "chunk_id": "87::chunk_18", "document_index": 87, "latency_s": 0.6386746000061976, "prompt_toks": 5676, "completion_toks": 59, "relevance_score": 5.8171895e-06}, "content": "Drug: Methadone | cid: 4095\nSource: psychonaut | Source description: Methadone (sold under trade names such as Dolophine and Methadose) is a synthetic opioid analgesic used for the treatment of moderate to severe pain and for the treatment of opioid addiction. It is commonly used to treat and manage the symptoms of opioid addiction. The subjective effects are similar to those of other synthetic opioids such as fentanyl, however, most users note a significantly stronger euphoria. Like dextropropoxyphene, the use of methadone is associated with cardiac arrhythmia, however it is more common with dextropropoxyphene than it is with methadone.\n\n                    Text: \n                    The risk of fatal opioid overdoses rise sharply after a period of cessation and relapse, largely because of reduced tolerance.[11] To account for this lack of tolerance, it is safer to only dose a fraction of one's usual dosage if relapsing. It has also been found that the environment one is in can play a role in opioid tolerance. In one scientific study, rats with the same history of heroin administration were significantly more likely to die after receiving their dose in an environment not associated with the drug in contrast to a familiar environment.[12]\n\nDangerous interactions\n\nWarning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).\n\n\n                    Context: \n                    This section discusses the increased risks associated with opioid overdose after cessation and relapse, highlighting the importance of reduced tolerance and environmental factors. It also provides a warning about dangerous drug interactions, emphasizing the need for harm reduction when combining substances. These details are crucial for understanding overdose dangers and safe usage practices.\n                "}
